epidermal-growth-factor and Soft-Tissue-Neoplasms

To evaluate the protective effect of low-dose dopamine given as continuous infusion in patients who undergo chemotherapy with the nephrotoxin cisplatin.. Forty-two patients who received high-dose cisplatin-containing chemotherapy entered a prospective, randomized, double-blind, placebo-controlled trial. Twenty-one patients received dopamine, and 21 received placebo. Patients were to receive either infusional dopamine 2 micrograms/kg/min over 48 hours or placebo. Cisplatin 125 mg/m2 was administered 12 hours after initiating dopamine (group D) or placebo (group P). This schedule was repeated twice, 1 week apart. Measurements of serum creatinine, urinary electrolytes and creatinine, urinary excretion of epidermal growth factor (EGF), ototoxicity, parameters of hematopoietic recovery, and duration of hospitalization were analyzed.. We observed an increase in serum creatinine level to a peak of 1.9 mg/dL (range, 0.8 to 7.8) in the dopamine group, in comparison to 1.4 mg/dL (range, 0.9 to 3.3) in the placebo group (P = .04). Urinary magnesium excretion increased and EGF excretion decreased in both groups. Urinary sodium, chloride, and potassium excretion were increased in both groups, but more so in the placebo group. Dopamine had no measurable effect on hearing loss, duration of hospitalization, or hematopoietic recovery.. The use of prophylactic dopamine increased peak serum creatinine levels relative to placebo and failed to prevent cisplatin-induced renal toxicity or ototoxicity. Determination of whether dopamine could reverse chemotherapy-induced renal damage would require a randomized prospective trial.

Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Creatinine; Cyclophosphamide; Dopamine; Double-Blind Method; Electrolytes; Epidermal Growth Factor; Etoposide; Female; Hearing Loss; Humans; Kidney Diseases; Male; Middle Aged; Prospective Studies; Sarcoma; Soft Tissue Neoplasms; Water-Electrolyte Imbalance

Calcifying aponeurotic fibroma (CAF) is a soft tissue neoplasm with a predilection for the hands and feet in children and adolescents. Its molecular basis is unknown. We used chromosome banding analysis, fluorescence in situ hybridization (FISH), mRNA sequencing (RNA-seq), RT-PCR, and immunohistochemistry to characterize a series of CAFs. An insertion ins(2;4)(q35;q25q?) was identified in the index case. Fusion of the FN1 and EGF genes, mapping to the breakpoint regions on chromosomes 2 and 4, respectively, was detected by RNA-seq and confirmed by RT-PCR in the index case and two additional cases. FISH on five additional tumours identified FN1-EGF fusions in all cases. CAFs analysed by RT-PCR showed that FN1 exon 23, 27 or 42 was fused to EGF exon 17 or 19. High-level expression of the entire FN1 gene in CAF suggests that strong FN1 promoter activity drives inappropriate expression of the biologically active portion of EGF, which was detected immunohistochemically in 8/9 cases. The FN1-EGF fusion, which has not been observed in any other neoplasm, appears to be the main driver mutation in CAF. Although further functional studies are required to understand the exact pathogenesis of CAF, the composition of the chimera suggests an autocrine/paracrine mechanism of transformation. Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Topics: Adolescent; Child; Child, Preschool; Chromosome Banding; Epidermal Growth Factor; Exons; Female; Fibroma; Fibronectins; Gene Fusion; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Recurrence; Soft Tissue Neoplasms

Desmoid tumors are benign but locally invasive myofibroblastic lesions that arise predominantly in the abdominal wall or shoulder and are prone to aggressive local recurrences. A perceived association between desmoid activity and the expression of growth factors during pregnancy or following trauma suggests a cause-and-effect relationship between growth factor stimulation and desmoid invasiveness. We used Boyden Chambers to quantify cell motility in order to determine the effect of growth factor stimulation on desmoid cell migration. Desmoid cell cultures were treated under serum-free conditions with epidermal growth factor (rhEGF) or transforming growth factor alpha (rhTGFalpha). Additional cell cultures were pretreated under serum-free conditions with the EGF receptor (EGFR) inhibitor AG1478, alone or in combination with the TGFbeta1 receptor inhibitor SB431542, and then stimulated with growth factor prior to being assayed for cell motility. The experiments demonstrated a direct dose-dependent relationship between rhEGF stimulation and desmoid motility. In contrast, rhTGFalpha was less effective at inducing cell migration. rhEGF-induced cell migration could be diminished, but not reduced to control levels, by inhibiting EGFR. When EGF and TGFbeta1 receptors were inhibited simultaneously, the level of rhEGF-induced cell migration was reduced significantly beyond the level of cell migration generated by inhibition of EGFR alone.

Topics: Benzamides; Cell Division; Cell Line, Tumor; Cell Movement; Culture Media, Serum-Free; Dioxoles; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Fibromatosis, Aggressive; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Integrin beta1; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Quinazolines; Receptors, Transforming Growth Factor beta; Recombinant Proteins; RNA, Messenger; RNA, Small Interfering; Soft Tissue Neoplasms; STAT3 Transcription Factor; Transforming Growth Factor alpha; Tyrphostins

The rare benign extra-abdominal desmoid tumor is characterized by aggressive invasion of normal tissue. Treatment is complicated by its recurrence, invasiveness, and persistence. The etiology is unknown and the pathophysiology is obscure. Because of exuberant fibroblastic proliferation with collagenous tissue being the primary tissue component, this desmoid tumor has been compared with keloids arising from excessive scar formation in healing wounds. Numerous cytokines are associated with signaling for growth and maintenance of mesenchymal cells. Altered expression of these proteins is associated with many pathologic conditions. It has been proposed that the enhanced expression of platelet-derived growth factor and its receptor characterize desmoid tumors. We tested the hypothesis that the exuberant fibrosis of desmoid tumors may have resulted from the initiation of the cascade of molecular events producing increased expression of cytokines. We used immunohistochemical analysis of cytokines in desmoid tumors compared with keloids and skin to localize the expression of cytokines. The results showed localized increased expression of the cytokines epidermal growth factor, transforming growth factor-beta, tumor necrosis factor-alpha, vascular endothelial growth factor, interleukin-1beta, and interleukin-6 in the endothelial cells of blood vessels in the tumors. Production of tumor necrosis factor-alpha and interleukin-1beta in tumor tissue was increased, but we did not find increased expression of platelet-derived growth factor. We concluded that the increased expression of cytokines associated with angiogenesis usually found in wound healing and invasive tumors may contribute to the pathophysiology of the desmoid tumor.

Topics: Adolescent; Adult; Aged; Endothelial Growth Factors; Epidermal Growth Factor; ErbB Receptors; Female; Fibroblast Growth Factor 1; Fibroblast Growth Factor 2; Fibromatosis, Aggressive; Humans; Interleukin-1; Interleukin-6; Lymphokines; Male; Platelet-Derived Growth Factor; Receptors, Fibroblast Growth Factor; Receptors, Interleukin-6; Receptors, Platelet-Derived Growth Factor; Receptors, Vitronectin; Soft Tissue Neoplasms; Transforming Growth Factor alpha; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

According to the autocrine hypothesis of cell growth, tumors, in contrast to normal tissue, might simultaneously express both a growth factor and its receptor, resulting in autoregulation and autostimulation of growth. In a related hypothesis, expression of either a growth factor or receptor might allow a tumor to escape exogenous controls on growth, and thereby correlate with malignant potential. Using immunohistochemistry, we investigated these hypotheses in 69 human soft tissue tumors (STT) by assaying for the expression of nerve growth factor and receptor, epidermal growth factor and receptor and platelet-derived growth factor. Both benign (B) and malignant (M) STT expressed a variety of factors and receptors. However, the frequency of any growth factor expression (90% M versus 55% B, p = 0.002) and of multiple factors (59% M versus 24% B, p = 0.006) was significantly greater in malignant tumors. Similarly, expression of any growth factor receptor (73% M versus 31% B, p = 0.001) and of multiple receptors (35% M versus 3% B, p = 0.002) was significantly more frequent in malignant STT. In terms of the autocrine hypothesis, growth factor/receptor co-expression was significantly more common in malignant STT (63% M versus 17% B, p = 0.0002). We conclude that (a) expression of both single and multiple growth factors and receptors was significantly more frequent in malignant STT; (b) support for an autocrine growth mechanism through simultaneous factor/receptor co-expression can be found in both benign and malignant STT; (c) co-expression, however, was more frequent in the malignant tumors; and (d) overall, growth factor and receptor expression, as well as co-expression, was related to biologic potential among human soft tissue tumors.

Topics: Epidermal Growth Factor; ErbB Receptors; Growth Substances; Humans; Immunoenzyme Techniques; Immunohistochemistry; Nerve Growth Factors; Parotid Gland; Phenotype; Platelet-Derived Growth Factor; Receptors, Cell Surface; Receptors, Nerve Growth Factor; Soft Tissue Neoplasms